Cancer Biology & Medicine

Papers
(The TQCC of Cancer Biology & Medicine is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Multiplex imaging reveals the architecture of the tumor immune microenvironment91
Emerging roles of plasmacytoid dendritic cell crosstalk in tumor immunity44
Therapeutic revolution for inoperable stage III non-small cell lung cancer in the immune era34
Frequent low dose alcohol intake increases gastric cancer risk: the Health Examinees-Gem (HEXA-G) study30
The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study29
Hot issues in triple-negative breast cancer28
Drug clinical trials on high-grade gliomas: challenges and hopes25
Metabolic regulation of innate immunity in cancer immunotherapy23
Recent advances in the systemic treatment of gastrointestinal stromal tumors23
Highlighted multi-modifications of enzymes: a novel succinylation mediated by histone acetyltransferase 1 in tumors23
The interplay between H3K36 methylation and DNA methylation in cancer18
Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells18
A causal variant rs3769823 in 2q33.1 involved in apoptosis pathway leading to a decreased risk of non-small cell lung cancer17
Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling16
Evolving molecular subtyping of breast cancer advances precision treatment16
Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies16
Peptide drugs: a new direction in cancer immunotherapy15
Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives14
Single-arm trials for domestic oncology drug approvals in China13
JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ13
Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei13
The outpost against cancer: universal cancer only markers13
Cancer risk in relatives of BRCA1/2 pathogenic variant carriers in a large series of unselected patients with breast cancer12
Development of small molecule drugs targeting immune checkpoints12
Next-generation antibody–drug conjugates revolutionize the precise classification and treatment of HER2-expressing breast cancer11
Advances in MET tyrosine kinase inhibitors in gastric cancer11
Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance11
2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma10
Comprehensive characterization of CRC with germline mutations reveals a distinct somatic mutational landscape and elevated cancer risk in the Chinese population9
Using triple radio-immunotherapy to overcome cancer immunotherapy resistance9
Circulating cell-free mtDNA as a new biomarker for cancer detection and management9
Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer8
DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation8
Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma8
Comparative profiling of immune genes improves the prognoses of lower grade gliomas8
The Warburg effect drives dedifferentiation through epigenetic reprogramming8
Expanding horizons in overcoming therapeutic resistance in castration-resistant prostate cancer: targeting the androgen receptor-regulated tumor immune microenvironment7
Early detection of gastric cancer in China: progress and opportunities7
Research progress in hepatitis B virus covalently closed circular DNA7
The role of DLL1 in long-term vascular normalization and cancer immunotherapy7
Update on diffuse large B-cell lymphoma: highlights from the 2022 ASCO Annual Meeting7
Impact of cancer diagnosis on life expectancy by area-level socioeconomic groups in New South Wales, Australia: a population-based study7
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification6
Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies6
Epigenetic reprogramming in small cell lung cancer6
Microsurgery vs. radiosurgery for the treatment of multiple metastases in the brain: a retrospective cohort study6
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up6
Metabolic regulation of immune responses to cancer6
Roles of eIF5A in the immunosurveillance of cellular senescence6
Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy6
Bacterial outer membrane vesicle-based cancer nanovaccines5
Safety and efficacy of intraoperative radiation therapy using a low-energy X-ray source for resectable pancreatic cancer: an interim evaluation of an ongoing prospective phase II study5
Cohort profile: design and methods of the Chinese colorectal, breast, lung, liver, and stomach cancer screening trial (C-BLAST)5
Circular RNAs: implications of signaling pathways and bioinformatics in human cancer5
Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies5
Detection and surveillance of circulating tumor cells in osteosarcoma for predicting therapy response and prognosis5
Intercellular transmission of cGAS-STING signaling in cancer5
EZH2 identifies the precursors of human natural killer cells with trained immunity5
Effectiveness of colorectal cancer screening integrating non-genetic and genetic risk: a prospective study based on UK Biobank data5
Single-cell RNA sequencing reveals spatial heterogeneity and immune evasion of circulating tumor cells5
The mutation landscape of multiple cancer predisposition genes in Chinese familial/hereditary breast cancer families5
Genetic polymorphisms in genes regulating cell death and prognosis of patients with rectal cancer receiving postoperative chemoradiotherapy5
Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA5
IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation5
Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives5
Cancer immunology and immunotherapy5
Reflections on the withdrawal of medical articles and the development of writing and publishing standards5
Immune checkpoint inhibitors: breakthroughs in cancer treatment4
The active surveillance management approach for patients with low risk papillary thyroid microcarcinomas: is China ready?4
Multiple myeloma survival in New South Wales, Australia, by treatment era to 20204
Progress in clinical diagnosis and treatment of colorectal cancer with rare genetic variants4
Expert opinion on translational research for advanced glioblastoma treatment4
Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies4
Multifaceted efforts of governments, medical institutions, and financial organizations contribute to reducing the health inequality caused by economic differences4
Efficacy and safety of anlotinib combined with the STUPP regimen in patients with newly diagnosed glioblastoma: a multicenter, single-arm, phase II trial4
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB4
Roles of cancer-associated fibroblast functional heterogeneity in shaping the lymphatic metastatic landscape: new insights and therapeutic strategies4
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente4
Progress in oncolytic viruses modified with nanomaterials for intravenous application4
Inconsistent radiotherapy effects between primary tumors and axillary lymph nodes4
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival4
SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation4
0.075977087020874